A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Risankizumab (Primary) ; Risankizumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 28 Feb 2018 Planned End Date changed from 13 Nov 2019 to 15 Apr 2020.
- 28 Dec 2017 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 Planned End Date changed from 17 Jun 2019 to 13 Nov 2019.